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Background: Helichrysum species are used extensively for stress-related ailments and as dressings for wounds
normally encountered in circumcision rites, bruises, cuts and sores. It has been reported that Helichysum species are
used to relief abdominal pain, heart burn, cough, cold, wounds, female sterility, menstrual pain.
Results: From the extracts of Helichrysum foetidum (L.) Moench, six known compounds were isolated and identified.
They were 7, 4′-dihydroxy-5-methoxy-flavanone (1), 6′-methoxy-2′,4, 4′-trihydroxychalcone (2), 6′-methoxy-2′,4-
dihydroxychalcone -4′-O-β-D-glucoside (3), apigenin (4), apigenin-7-O-β-D-glucoside (5), kaur-16-en-18-oic acid
(6) while two known compounds 3,5,7-trihydroxy-8-methoxyflavone (12), 4,5-dicaffeoyl quinic acid (13) together
with a mixture of phytosterol were isolated from the methanol extract of Helichrysum mechowianum Klatt. All the
compounds were characterized by spectroscopic and mass spectrometric methods, and by comparison with
literature data. Both extracts and all the isolates were screened for the protease inhibition, antibacterial and antifungal
activities. In addition, the phytochemical profiles of both species were investigated by ESI-MS experiments.
Conclusions: These results showed that the protease inhibition assay of H. foetidum could be mainly attributed to the
constituents of flavonoids glycosides (3, 5) while the compound (13) from H. mechowianum contributes to the
stomach protecting effects. In addition, among the antibacterial and antifungal activities of all the isolates, compound
(6) was found to possess a potent inhibitor effect against the tested microorganisms. The heterogeneity of the genus is
also reflected in its phytochemical diversity. The differential bioactivities and determined constituents support the
traditional use of the species. Molecular modelling was carried out by computing selected descriptors related to drug
absorption, distribution, metabolism, excretion and toxicity (ADMET).
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Table 1 Activity (% inhibition) of Helichrysum crude extracts and
major isolated compounds (1–6) in protease inhibition assays
using pepsin and subtilisin
Inhibition of pepsin (%)
Sample Concentration (μg/ml)
50 25 10 1 0.1 0.01
H. mechowianum 22.8 18.8 12.0 0.3 10.9 5.4
H. foetidum 37.4 35.6 17.8 nd 12.6 7.1
1 nd 39.5 nd −14.2 −1.5 0.4
2 nd 15.9 9.2 −1.4 nd 0.3
3 37.4 37.4 20.1 18.2 19.4 8.0
4 11.6 0.2 nd 0.2 7.8 1.8
5 46.3 37.2 15.1 18.6 −5.3 −2.9
6 25.0 −3.6 nd −39.0 −1.2 −8.0
12 10.5 0.7 Nd 0.4 6.2 2.3
13 14.7 16.4 11.8 13.7 13.1 6.1
Inhibition of subtilisin (%)
H. mechowianum −4.8 0.2 3.0 −0.1
H. foetidum 0.9 2.1 4.0 3,8
1 nd nd nd nd
2 −11.6 −26.2 13.2 nd
3 9.7 4.2 6.0 3.0
4 11.5 7.8 6.8 nd
5 9.2 0.3 1.0 −4.8
6 −11.6 nd −5.5 16.6
12 11.1 8.9 7.5 Nd
13 8.3 5.2 7.1 3.2
nd not detected
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The genus Helichrysum (Compositae) consists of more
than 600 species with a major center of distribution in
South Africa [1]. Several Helichrysum species have
been used in folk medicine of different countries for
the protection of post-harvest food [2]. Moreover,
Helichrysum species are used extensively for stress-
related ailments and as dressings for wounds normally
encountered in circumcision rites, bruises, cuts and
sores [3]. It has been also reported that Helichysum
species are used to relief abdominal pain, heart burn,
cough, cold, wounds, female sterility, menstrual pain
[4] and to treat some diseases such as gastric [5–7],
gastroduodenal, gastric ulcers and gastritis [8], stom-
ach damage [9, 10], acute hepatitis, fever, or oedema
[11], diuretic, inflammatory, allergic [12, 13]. In
addition, some of these species have been reported to
possess antimicrobially active compounds [14–16].
Chemical studies on Helichrysum species have
been carried out by many investigators and the pres-
ence of flavonoids, phloroglucinols, α-pyrones, cou-
marins and terpenoid compounds has been reported
[17–25]. H. foetidum has been assessed to treat in-
fluenza, infected wounds, herpes, eye problems,
menstrual pains and to induce trance and possess
antifungal properties [2, 26]. H. mechowianum is
used for the treatment of stomach damage, cephalgy
[9, 27] and possesses ulcerogenic activity [28, 29]. In
continuation of these studies, we extended our
search for biologically active compounds from Heli-
chrysum species [17, 18] to the protease-inhibiting
activity of extracts and isolated compounds from
Helichrysum foetidum and Helichrysum mechowia-
num using a fluorescence resonance energy transfer
(FRET) protease pepsin inhibition assay as pharma-
cological model for anti-ulcer compounds [30].
Beside excessive stomach acid and Helicobacter
pylori, pepsin is one of the major factors in the
pathophysiology of peptic ulcer disease and reflux
oesophagitis. In addition, the antibacterial and anti-
fungal effects of both species against Bacillus subtilis
and the yeast Cladosporium cucumerinum were evalu-
ated respectively.
The chemical profile of methanol extracts of H.
mechowianum and H. foetidum was investigated. To
our knowledge, this is the first report about constitu-
ents of H. mechowianum. The compounds identified
have been reported previously from other Helichrysum
species in different compositions.
In order to assess the drug-likeness profiles of the
isolated metabolites, low energy computer models
were generated and a number of ADMET-related de-
scriptors calculated, with the view of drug metabolism
and pharmacokinetics (DMPK) evaluation.Results and discussion
Biological tests
The methanol leaf extracts of Helichrysum foetidum and
Helichrysum mechowianum showed significant activity
in the pepsin protease FRET assay while no activity was
detected against the serine protease subtilisin (Table 1).
The extract of H. foetidum exhibited the higher pepsin
protease inhibition (37.4 and 35.6 % inhibition at 50 and
25 μg/ml) (Table 1). Therefore also the previously iso-
lated constituents 1–6 (Fig. 1) from H. Foetidum and
12–13 from H. mechowianum were tested. The best
results at a concentration of 50 μg/ml were obtained
with apigenin-7-O-β-D-glucoside (5) and 6′-methoxy-
2′,4-dihydroxychalcone-4′-O-β-D-glucoside (3) with a
moderate inhibition activity of 46.3 and 37.4 % respect-
ively (Table 1) while 3,5,7-trihydroxy-8-methoxyflavone
(12), 4,5-dicaffeoyl quinic acid (13) showed weak activ-
ity. These results suggest that the inhibition activity on
the aspartate protease observed with H. foetidum extract
could be mainly attributed to the glycosidic compounds
(3) and (5). Contrarily, in the inhibition assay with the
Fig. 1 compounds 1–6 isolated from leaves and flowers of H. foetidum and compounds 12–13 from leaves of H. Mechowianum
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the isolated substances of both species show significant
activity (Table 1). We can conclude that the substances
present in the crude extract of H. foetidum are selective
for aspartate proteases. Observed negative results may
be due to the auto-fluorescence debris of subtilisin
cleavage of these compounds resulting in fluorescent
residues or the absence of bioaffinity interactions be-
tween the substances present in the crude extract of
H. foetidum with the serine protease subtilisin [31]. The
observed protease inhibiting activity may have mucosal
protective effects and therefore may help to reduce pep-
tic ulceration. From the Black birch fungus (Inonotus
obliquus), which is used in folk medicine in Russia for
the treatment of gastrointestinal tract disorders, also the
flavonoidal fraction was shown to possess antiulcerous
activity [31].
In addition, the crude extract of both species and all
the isolated compounds were subjected to in vitro anti-
microbial assay against the reference strains of bacteria
Bacillus subtilis and yeast (Cladosporium cucumerinu).
It has been reported that extracts having MIC values
below 8000 μg/ml possess some antimicrobial activity
[32]. MIC values below 1000 μg/ml are considered note-
worthy [33, 34]. Thus, the crude extract having activities
of 1000 μg/ml or lower against all the pathogens studied
demonstrated potential anti-infective properties. Com-
pounds having antimicrobial activities less than 64 μg/ml are accepted as having notable antimicrobial activity
[33] and those compounds exhibiting activity at concen-
trations below 10 μg/ml are considered “clinically signifi-
cant” [32, 33]. According to this observation, the crude
leaf and flower extracts of H. foetidum showed a signifi-
cant and concentration dependent growth inhibition of
Bacillus subtilis of of 85.4 % at a concentration of 1 mg/
ml and of 21.8 % at a concentration of 0.1 mg/ml
whereas the crude extract of H. mechowianum at con-
centrations of 1 mg/ml and 0.1 mg/ml causes a moder-
ate growth inhibition of 36,2 and 29,8 % respectively
(Table 2). Likewise, the crude leave and flower extracts
of H. Foetidum also exhibit antifungal activity against
Cladosporium cucumerinu shown by the development of
inhibition zones on the bioautography plate. In contrast,
extracts of H. mechowianum were slightly active against
this fungus.
Furthermore, all of the isolated compounds were sub-
jected to in vitro antimicrobial assay. It was interesting to
note that compounds (1–6) from H. Foetidum exhibited
notable growth inhibition range of 85.0 to 75.0 % against
Bacillus subtilis and a range of 70 to 56 % against the yeast
Cladosporium cucumerinu at a concentration of 1 mg/ml
whereas compounds (12–13) from H. mechowianum
showed a moderate growth inhibition range of 40.2 to
30.8 % at 1 mg/ml against Bacillus subtilis (Table 2). Of all
the isolated, compound (6) exhibited the highest sensitiv-
ity growth inhibition of Bacillus subtilis of 85.0 % at a
Table 2 Antimicrobial activity ((%)of Helichrysum crude extracts
and isolated compounds 1–6, 12–13 from H. Foetidum
Minimum inhibitory concentration ((%)
Sample Concentration (mg/ml)
Cladosporium cucumerinum Bacillus subtilis
1 0.1 1 0.1
H. mechowianum 13.8 10.4 36.2 29.2











CIP Ciprofloxacin antibacterial standard, AMP Amphotericin-B antifungal standard,
nd not detected
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active component of the crude flower extract of H. Foeti-
dum (Table 2).
The results of the work indicate that diterpenoid pos-
sess antimicrobial against the gram positive bacterium.
This antibacterial activity of H. foetidum extract might
be associated to the high content of kaurenoic acid (6).
This justifies the use of these plants species in folk medi-
cine and corroborated with the previous reports on the
antibacterial activities for Helichrysum species [2, 35,
36]. Kaur-16-en-19-oic acid isolated from extract of the
Asteraceae (Senecio erechtitoides and Wedelia calendula-
ceae) was previously shown to possess high inhibitory
activity against several bacterial strains [37, 38].
Chemical constituents
The main constituents of both species were character-
ized by detailed ESI-MS investigations. The combination
of LC-MS, MS/MS and FTICR-HRMS allowed the de-
tection of various components simultaneously. The MS
experiments show, that H. foetidum and H. mechowia-
num possess different chemical compositions. The leaf
extract of H. foetidum is dominated by the chalcones 2
and 3, the flavonoids 4 and 5 and by diterpenoids [18]
whereas main constituents of H. mechowianum are qui-
nic acid derivatives with a less prominent bioactivity
profile.
A more detailed ESI-MS investigation of the crude ex-
tract of Helichrysum mechowianum indicates (Additional
file 1) the presence of quinic acid (7, ESI-FTICR-MS:
[M - H]−, m/z 191.05578, calc. for C7H11O6
− 191.05556,ferulic acid (8, ESI-FTICR-MS: [M - H]−, m/z 193.05028,
calc. for C10H9O4
− 193.05008, chlorogenic acid (9, ESI-
FTICR-MS: [M - H]−, m/z 353.08751, calc. for C16H17O9
−
,
353.08726, three isomers of dicaffeoyl quinic acid (10,
ESI-FTICR-MS: [M - H]−, m/z 515.11949, calc. for
C25H23O12
− 515.11895, and three isomers of methyl de-
rivatives of 10 (11, ESI-FTICR-MS: [M - H]−, m/z
529.13539 calc. for C26H25O12
− 529.46950.
Compounds 7–11 were detected before in other
Helichrysum species. Mono- and dicaffeoyl quinic acids
are the main constituents of the Mediterranean herb
H. italicum [38, 39] and are also present in the French
H. stoechas var. olonnense [40]. Both are used as digestive.
A similar compound composition is known for the
Artichoke; Cynara scolymus L., which is used for its
choleretic, lipid-lowering, hepatostimulating, and appetite-
stimulating actions [41]. Extracts and constituents of
artichoke were also shown to possess antibacterial and
antifungal activities, however, Extracts and constituents of
H. mechowianum showed least efficiency antifungal prop-
erties against the yeast Cladosporium cucumerinum. The
observed quinic acid derivatives might be responsible for
the stomach protecting effects of H. mechowianum.
Chromatographic separation of the partitioned ex-
tracts of H. mechowianum resulted in the isolation of a
phytosterol mixture from the n-heptane fraction, 3,5,7-tri-
hydroxy-8-methoxyflavone (12, ESI-FTICR-MS: [M+Na]+
m/z 323.05297 calc. for C16H12O6Na 323.05261) from the
ethyl acetate fraction and 4,5-dicaffeoyl quinic acid (13,
ESI-FTICR-MS: [M -H]−, m/z 515.12168 calc. for
C25H23O12
− 515.11950) from the water fraction. The relative
composition of the phytosterol fraction was determined by
GCMS as campesterol (2 %), stigmasterol (9.3 %), campest-
7-en-3-ol (61.4 %), chondrillasterol (18.9 %), β-sitosterol
(61.4 %) and an unidentified sterol (1.2 %). The compounds
(12) [42] and (13) [43] were identified by comparison of
spectral data with literature data. In addition, the position
of the caffeoyl residues in compound (13) was determined
by 2D NMR measurements. In particular, HMBC correla-
tions from H-4 and H-5 of the quinic acid to C-9′, C-8′
and C-7′ of the caffeoyl residues indicates the substitution
at position 4 and 5 (Table 3). Since this compound is re-
ported to possess cytotoxic and apoptose inducing activity
[44, 45], the anticancer activity against the prostate cancer
cell line PC-3 was tested. However in concentrations of 50
nM or 50 μM no effect was observed with this cell line
(Table 4).
In silico pharmacokinetics assessment
Many bioactive compounds do not make it to clinical
trials because of adverse pharmacokinetic properties. It
therefore becomes imperative to access the pharmaco-
kinetic profiles of potential drugs early enough in order
to access their potential for further development. A
Table 3 1H and 13C NMR assignments for compounds (1–5, 12)
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Table 4 LC/MS data, deprotonated and protonated molecules (m/z) for peaks, including the retention times (Rt), MS/MS
experiments of the constituents found in MeOH extract of Helichrysum mechowianum and Helichrysum foetidum
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529.135391 [M-H]− C25H24O12 Mixture of three dicaffeoyl
quinic acid





529.135391 [M-H]− C26H26O1 Mixture of thtree dicaffeoyl
quinic acid methyl ether
21.4 301.2166660 [M-H]− C20H30O2 kaur-16-en-18-oic acid
(5β,8α,9β,10α,13α)
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scriptors used to assess the drug-likeness profiles of the
isolated metabolites have been summarized in Table 2.
These include the #stars or ‘drug-likeness’ parameter,
the molecular weight (MW), the solvent accessible sur-
face area (SASA), along with its hydrophobic compo-
nent (FOSA) and hydrophilic component (FISA), the
molecular volume, the number of hydrogen bond ac-
ceptors (HBA) and donors (HBD), the n-octanol/water
partition coefficient (log P), the solubility parameter
(log S), the predicted IC50 values for the blockage of
the human-ether-a-go-go potassium ion (HERG K+)
channels (logHERG), predicted permeability of Caco-2
cells, the blood–brain barrier partition coefficient (log
BB), permeability of Madin-Darby canine kidney
(MDCK) monolayers, skin permeability (log Kp), the
number of predicted primary metabolites (#metab), the
binding affinity to human serum albumin (log KHSA),
the percentage human oral absorption (PHOA), the
number of violations of Lipinski’s ‘Rule of Five’ (Ro5)
and Jorgensen’s ‘Rule of Three’ (Ro3) and the polar sur-
face area (PSA). The range of values of each parameter
for 95 % of known drugs have been given beneath
Table 2. Five of these compounds (1, 2, 3, 5 and 12)
showed #star = 0, which indicates that all the computed
parameters fell within the recommended range for
95 % of known drugs. Meanwhile, compounds 4 and 6
showed only #star = 1. An overall ADME-compliance
score, drug-likeness parameter (indicated by #stars),
was used to assess the pharmacokinetic profiles of the
isolated compounds. The #stars parameter indicates the
number of property descriptors computed by QikProp
[46], which fall outside the optimum range of values
for 95 % of known drugs. The methods implemented
were developed by Jorgensen et al. [47–49] (Table 5).Materials and methods
General methods
Silica gel (Merck, 63–200 μm) and Sephadex LH-20
(Supelco) were used for column chromatography. Frac-
tions were monitored by TLC using precoated silica gel
plates 60 F254 (Merck). Spots were visualized by heating
silica gel plates sprayed with vanillin-H2SO4 in MeOH.
The 1H and 13C NMR spectra were recorded on a Varian
Mercury 300 spectrometer at 300.22 and 75.50 MHz,
respectively. 1H and 2D NMR spectra were recorded on a
Varian VNMRS 600 system operating at a proton NMR
frequency of 599.83 MHz equipped with a 5 mm inverse
detection cryoprobe using standard CHEMPACK 4.1
pulse sequences (COSY, ROESY, 1DNOESY, HSQCAD,
HMBCAD) implemented in Varian VNMRJ 2.2C spec-
trometer software. Chemical shifts were referenced to
internal TMS (δ = 0 ppm, 1H) and CDCl3 (δ = 77.0 ppm,
13C) or CD3OD (δ = 49.0 ppm,
13C), respectively. The high
resolution ESI mass spectra were obtained from a Bruker
Apex III Fourier transform ion cyclotron resonance
(FTICR) mass spectrometer (Bruker Daltonics, Billerica,
USA) equipped with an Infinity™ cell, a 7.0 Tesla super-
conducting magnet (Bruker, Karlsruhe, Germany), an
RF-only hexapole ion guide and an external APOLLO
electrospray ion source (Agilent, off axis spray, voltages:
endplate, -3.700 V; capillary, −4.200 V; capillary exit,
100 V; skimmer 1, 15.0 V; skimmer 2, 10.0 V). Nitrogen
was used as drying gas at 150 °C. The sample solutions
were introduced continuously via a syringe pump with a
flow rate of 120 μl/h. All data were acquired with 512 k
data points and zero filled to 2048 k by averaging 32 scans.
The XMASS Software (Bruker, Version 6.1.2) was used for
evaluating the data. The positive ion ESI mass spectra and
the collision-induced dissociation (CID) mass spectra were
obtained from a TSQ Quantum Ultra AM system
Table 5 Computed molecular descriptors for the assessment of the DMPK profiles of the major isolated metabolites and the
recommended range for 95 % of known drugs
Metabolite a#stars bCNS cMW (Da) dSASA eFOSA fFISA gvolume hHBD iHBA jlog P klog S
1 0 -1 286.3 506.7 157.9 145.1 880.6 2 5 1.9 -3.3
2 0 -2 286.3 548.9 110.0 181.5 920.6 2 4 2.3 -3.4
3 0 -2 270.2 491.3 0 200.4 827.7 2 4 1.7 -3.4
4 1 -2 448.4 734.5 249.3 263.0 1311.1 5 13 0.4 -3.1
5 0 -2 448.4 683.4 261.7 245.6 1264.2 5 14 -0.1 -3.0
6 1 -1 304.5 523.0 419.7 77.8 1007.6 1 2 4.8 -4.9
12 0 -2 284.3 504.1 26.4 215.2 856.2 3 4 1.5 -3.2
13 5 -2 516.5 839.4 183.4 *386.8 1495.9 *7 11 1.1 -4.5
Metabolite llogHERG mCaco-2 nlog BB oMDCK plog Kp
q#metab rlog KHSA
sPHOA tRo5 uRo3 vPSA
1 -4.49 417.0 -0.9 192.2 -3.2 5 -0.06 84.7 0 0 83.4
2 -5.45 188.1 -1.7 81.3 -3.2 4 -0.04 80.9 0 0 93.5
3 -5.06 124.7 -1.4 52.1 -3.9 3 -0.01 74.4 0 0 101.0
4 *-6.01 31.8 -3.1 11.9 -4.2 7 -0.79 43.2 1 1 168.1
5 -5.17 46.5 -2.4 17.9 -4.6 8 -0.71 56.4 0 1 162.1
6 -0.99 459.4 -0.1 271.4 -2.8 2 0.79 *100 0 0 42.7
12 -4.97 90.3 -1.6 36.8 -4.2 5 -0.10 70.5 0 0 109.1
13 -4.99 *0.5 *-4.9 *0.2 -6.3 6 -0.63 0 3 1 235.6
*Property which falls outside the recommended range for 95 % of known drugs; aNumber of computed properties which fall outside the required range for 95 %
of known drugs (recommended range 0 to 5); b Activity in the central nervous system in the scale −2 (inactive) to +2 (active); cMolar weight (range for 95 % of
drugs: 130–725 Da); dThe solvent accessible surface area (recommended range 300.0 to 1000.0 Å2); eThe hydrophobic component of the solvent accessible surface
area (recommended range 0.0 to 750.0 Å2); fThe hydrophilic component of the solvent accessible surface area (recommended range 7.0 to 330.0 Å2); gTotal
volume of molecule enclosed by solvent-accessible molecular surface, in Å3 (probe radius 1.4 Å) (range for 95 % of drugs: 500 to 2000 Å3); hNumber of hydrogen
bonds donated by the molecule (range for 95 % of drugs: 0 to 6); iNumber of hydrogen bonds accepted by the molecule (range for 95 % of drugs: 2–20); jLogarithm of
partitioning coefficient between n-octanol and water phases (range for 95 % of drugs: −2 to 6.5); kThe predicted aqueous solubility, with S in mol/dm3 (range for 95 % of
drugs: −6.5 to 0.5); lPredicted IC50 value for blockage of HERG K
+ channels (concern <−5); mPredicted apparent Caco-2 cell membrane permeability in Boehringer–Ingelheim
scale, in nm/s (range for 95 % of drugs: < 5 low, > 500 high); nLogarithm of predicted blood/brain barrier partition coefficient (range for 95 % of drugs: −3.0 to 1.0); oThe
predicted apparent MDCK permeability in nm/s (<25 poor, > 500 great); pThe predicted skin permeability (range for 95 % of drugs: −8.0 to −1.0); qNumber of likely metabolic
reactions (range for 95 % of drugs: 1–8); rLogarithm of predicted binding constant to human serum albumin (range for 95 % of drugs: −1.5 to 1.5); sThe predicted percentage
human oral absorption (>80 % high, < 25 % poor); tNumber of violations of Lipinski’s ‘Rule of Five’ (Recommended maximum 4); uNumber of violations of Jorgensen’s ‘Rule
of Three’ (Recommended maximum 3); vVan der Waals surface area of polar nitrogen and oxygen atoms (range for 95 % of drugs: 7.0 to 200.0 Å2)
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age 3.0 kV, sheath gas: nitrogen; vaporizer temperature:
50 °C; capillary temperature: 250 °C; The MS system is
coupled with a Surveyor Plus micro-HPLC (Thermo Elec-
tron), equipped with a RP18 column (5 μm, 150 × 1 mm,
Hypersil GOLD, Thermo Scientific). For the HPLC a gradi-
ent system was used starting from H2O:CH3CN 90:10
(each of them containing 0.2 % HOAc) to 5:95 within
15 min and then hold on 5 % for further 30 min; flow rate
70 μl/min. Sterols were determined by GC-MS (Voyager/
Trace GC 2000, Thermo Quest CE Instruments): 70 eV
EI, source temp. 200 °C; column ZB-5 (Phenomenex,
30 m × 0.25 mm, 0.25 μm film thickness); inj. temp. 250 °
C, interface temp. 300 °C; carrier gas He, flow rate 1.0 ml/
min, constant pressure mode; splitless injection, column
temp. program: 60 °C for 1 min, then raised to 300 °C at a
rate of 10 °C/min to 290 °C for 15 min.
Plant material
The plant materials were collected and identified by Elias
Ndive, a botanist from Limbé Botanic Garden, on March2009 near the town of Buea on the eastern slopes of
Mount Cameroon in the South West Province of
Cameroon. Voucher specimens (H. foetidum (L.) Moench:
SCE2463, H. mechowianum Klatt: SCE2467) are deposited
in the Herbarium of Limbé Botanic Garden.Extraction and isolation
Leaves and flowers of H. foetidum and leaves of H. mecho-
wianum were extracted exhaustively with 90 % methanol
for a period of 72 h. The solvent was removed by evapor-
ation under reduced pressure. From the crude flower
extract of H. foetidum, by purification with successive col-
umn and preparative TLC chromatography on silica gel
using a chloroform/methanol gradient systems,the com-
pounds 7,4′-dihydroxy-5-methoxy-flavanone (1) and kaur-
16-en-18-oic acid (6) were obtained while the compounds
6′-methoxy-2′,4,4′-trihydroxychalcone (helichrysetin) (2),
6′-methoxy-2′,4-dihydroxychalcone-4′-O-β-D-glucoside
(3), apigenin (4), apigenin-7-O-β-D-glucoside (5) were iso-
lated from the leaves and flowers of H. Foetidum.
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wianum leaves was partitioned successively with n-hept-
ane and ethyl acetate. The n-heptane and the ethyl
acetate extracts were further purified by silica gel col-
umn chromatography using n-hexane/ethyl acetate gra-
dient systems resulting in the isolation of a phytosterol
fraction and of 3,5,7-trihydroxy-8-methoxyflavone (12),
respectively. The water fraction was further separated
using Diaion HP20 eluted with water, methanol, ethyl
acetate and acetone followed by chromatography of the
methanol fraction on Sephadex LH20 to give 4,5-dicaf-
feoyl quinic acid (13). The crude extracts of H. foetidum
and H. mechowianum were analyzed by LC-ESI-MS,
MS/MS and FTICR-HRMS.
7,4′-dihydroxy-5-methoxy-flavanone (1): 1H NMR
(DMSO-d6): δ 9.60 (1H, brs, OH), 7.28 (2H, d, 8.6, H2′/
6′), 6.77 (2H, d, 8.6, H3′/5′), 6.04 (1H, d, 2.2, H6), 5.94
(1H, d, 2.2, H8), 5.32 (1H, dd, 12.6/2.9, H2), 3.72 (3H, s,
OMe), 2.98 (1H, dd, 16.3/12.6, H3b), ca. 2.5 (1H, m, super-
imposed by DMSO, H3a). 13C NMR (DMSO-d6) δ
79.0(C2), 42.4(C3), 196.3(C4), 163.0(C5),104.6(C6),167.1
(C7),95.4(C8),162.8(C9),101.6(C10), 129.6(C1′), 127.6(C2′
/C6′), 115.0(C3′/C5′), 157.6(C4′), 55.4 (OMe).
6′-methoxy-2′,4,4′-trihydroxychalcone (2): 1H NMR
(MeOD +CDCl3): δ 7.73 (1H, d, 16.0, Hα), 7.68 (1H, d,
16.0, Hβ), 7.49 (2H, d, 8.6, H2/6), 6.84 (2H, d, 8.6, H3/
5), 5.99 (1H, d, 2.2, H3′),5.96 (1H, d, 2.2, H5′), 3.93
(OMe) 13C NMR (MeOD +CDCl3): δ 193.6 (C =O),
168.2 (C4′), 165.9 (C2′), 164.2 (C6′), 160.5 (C4), 143.5
(CH-β), 131.0 (C2/6), 128.0 (C1), 125.2 (CH-α), 116.6
(C3/5), 106.3 (C1′), 96.9 (C5′), 92.2 (C3′), 56.2 (OMe).
6′-methoxy-2′,4-dihydroxychalcone-4′-O-β-D-glucoside
(3): 1H NMR (MeOD): δ 7.72 (1H, s, Hα), 7.71 (1H, s,
Hβ), 7.51 (2H, d, 8.7, H2/6), 6.83 (2H, d, 8.7, H3/5), 6.31
(1H, d, 2.2, H3′), 6.24 (1H, d, 2.2, H5′), 3.95 (3H, s,
OMe), glucose moiety: δ 4.99 (1H, d, 7.5, H1″),
4.24(H2″), 3.61(H3″), 3.60(H4″), 3.53(H5″), 3.80–3.90
(H6″), 13C NMR (MeOD) δ 193.6 (C =O), 168.2 (C4′),
165.9 (C2′), 164.2 (C6′), 160.5 (C4), 143.5 (CH-β), 131.0
(C2/6), 128.0 (C1), 125.2 (CH-α), 116.6 (C 3/5), 106.3
(C1′), 96.9 (C5′), 92.2 (C3′), 56.2 (OMe) glucose moiety:
δ 73.7(C1″), 71.0(C2″), 77.2(C3″), 78.9(C4″), 79.8(C5″),
60.6(C6″),
apigenin (4): 1H NMR (DMSO-d6): δ 12.96 (1H, s,
OH), 7.93 (2H, d, 8.8, H2′/6′), 6.93 (2H, d, 8.8, H3′/5′),
6.78 (1H, s, H3), 6.48 (1H, d, 2.0, H8), 6.19 (1H, d, 2.0,
H6). 13C NMR (DMSO-d6): δ 180.4 (C4), 164.94 (C5),
164.4 (C2), 162.6 (C4′), 160.7 (C9), 160.1 (C7), 129.3
(C2′/ C6′), 123.1 (C1′), 117.0 (C3′/ C5′), 109.3 (C10),
106.5 (C3), 104.8 (C6), 99.3 (C8).
apigenin-7-O-β-D-glucoside (5): 1HNMR(CD3OD, 500
MHz): aglycon moiety:δ 7.83 (2H,d, 8.8,H-2′/ H-6′),
6.92 (2H,d, 8.8, H-3′/ H-5′), 6.83 (1H,d, 2.1 Hz, H-6),
6.71 (1H,d, 2.1 Hz, H-8), 6.58 (1H,s, H-3), glucosemoiety: δ 4.90 (1H,d, 7.6, H-1″’), 3.50-3.25 (4H,m,H-2″,
3″, 4″, 5″), 3.87 (1H,dd, 11.9/ 2.2, H-6b″), 3.73
(1H,dd,11.9/ 5.4, H-6a″
13C NMR (DMSO-d6): δ 182.0
(C4), 164.3 (C5), 163.0 (C2), 161.5 (C4′), 161.1 (C9),
157.0 (C7), 128.7 (C2′/C-6′), 121.0 (C1′), 116.0 (C3′/
C5′), 105.4 (C10), 103.1 (C3), 99.9 (C6), 99.6 (C8), glu-
cose moiety: δ 105.1 (C1″), 78.6 (C5″), 77.5 (C3″), 74.8
(C2″), 71.8(C4″), 62.6 (C6″)
kaur-16-en-18-oic acid (6): 1H NMR (CDCl3): δ 4.79
(1H, s, H17), 4.73 (1H, s, H17), 2.63 (1H,brs), 2.15 (1H,
brd,13.9), 2.05 (2H, d, 2.0), 1.24 (3H, s, Me), 0.95 (3H, s,
Me) 13C NMR (CDCl3): δ 184.1 (C = O), 155.9 (C), 103.0
(CH2), 57.0 (CH), 55.1 (CH) 48.9 (CH2), 44.2 (C), 43.8
(CH), 43.7 (C), 41.3 (CH2), 40.7 (CH2), 39.7 (CH2), 39.6
(C), 37.8 (CH2), 33.1 (CH2), 28.9 (CH3), 21.8 (CH2), 19.1
(CH2), 18.4 (CH2), 15.6 (CH3).
3,5,7-trihydroxy-8-methoxyflavone (12): 1H NMR (CD
Cl3): δ 11.49 (1H, s, OH), 8.24 (2H, d, 7.1), 7.60-7.49
(3H, m), 6.70 (1H, s, OH), 6.46 (1H, s, OH), 6.33 (1H, s,
H6), 4.05 (3H, s, OMe). 13C NMR (CDCl3): δ 175.6
(C = O), 156.6 (C), 155.4 (C), 148.0 (C), 144.9 (C), 136.5
(C), 130.7 (C), 130.4 (CH), 128.8 (2 CH), 127.5 (2 CH),
126.9 (C), 98.2 (CH), 61.9 (OMe).
4,5-dicaffeoyl quinic acid (13): 1H NMR (MeOD): δ
7.585/7.507 (1H, d, 16.0, H7′/7″), 7.014/6.994 (1H, d,
2.0, H2′/2″), 6.905/6.890 (1H, dd, 8.2/2.0, H6′/6″),
6.739/6.733 (1H, d, 8.2, 5′/5″), 6.273/6.190 (1H, d, 16.0,
H8′/8″), 5.661 (1H, m, H5) 5.108 (1H, dd, 9.8/3, H4),
4.337 (1H, d, 3, H3), 2.284 (1H, brdd, 14.1 2.1, H2a), ca.
2.22 (2H, H6), 2.046 (1H, brd, 12.5, H2a).13C NMR
(MeOD): δ 178.9 (C7), 168.6/168.4 (C9′/9″), 149.6 (C4′/
4″), 147.6/147.4 (C7′/7″), 146.75/146.73 (C3′/3″), 127.7/
127.6 (C1′/1″), 123.1 (C6′/6″), 116.4 (C5′/5″), 115.1 (C2′/
2″), 114.8 (C8′/8″), 76.9 (C1), 76.6 (C4), 70.2 (C3), 69.3




Initially the extracts or purified constituents were dis-
solved in DMSO and the dilutions of samples tested
were made in the respective buffer for each enzyme,
i.e., 0.1 M sodium phosphate (pH 7.5) for subtilisin and
0.1 M sodium acetate (pH 4.4) for pepsin. Samples
(0.01 - 50 μg/ml) were pre-incubated with subtilisin (37
nM) or pepsin (1.7 nM) for 30 min and then, trans-
ferred to a black opaque microplate. The substrate
EDANS-DABCYL (2 μM), prepared in the specific buf-
fer for each protease, were automatically injected. The
final volume was 100 μl. Experiments were performed
separately for each protease, which was prepared at the
day of experiment. Reads were made for a period of
5 min, with 1 min intervals, and temperature controlled
at 37 °C. The mean, standard deviation and relative
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age of inhibition were calculated using the final fluores-
cence intensity measured.
Reagents
Pepsin from porcine gastric mucosa, Recombinant Type
VIII Subtilisin Carlsberg, Arg-Glu-(EDANS)-Ser-Gln-Asn-
Tyr-Pro-Ile-Val-Gln-Lys-(DALBCYL)-Arg fluorogenic sub-
strate (EDANS-DABCYL), DMSO spectrophotometric
grade were from Sigma-Aldrich, Sao Paulo, Brazil. Fluores-
cence bioassay data were collected with a multi detection
microplate reader SynergyTM HT (Bio-Tek® Instruments
Inc., Winooski, Vermont, USA), with 360 nm excitation
and 460 nm emission filters, and analyzed using KC4 soft-
ware (Bio-Tek®Instruments) and a Microsoft Windows XP.
Antibacterial assay
The antibacterial activity against a fluorescent Bacillus
subtilis [50] was determined with a fluorescence based
antibacterial growth inhibition assay. The fluorescence
was measured on a microtiter plate reader GENios Pro
(Fa. Tecan, excitation 510 nm; emission 535 nm). The
Bacillus subtilis strain 168 (PAbrB-IYFP) was maintained
on TY (tryptone-yeast extract) medium supplemented
with 1 % Bacto-tryptone, 0.5 % Bacto-yeast extract, 1 %
NaCl and Chloramphenicol (5 μg/ml). Erythromycin was
used as positive control for growth inhibition.
Antifungal assay
The antifungal activity against the phytopathogenic fun-
gus Cladosporium cucumerinum was tested by bioauto-
graphy on silica gel plates [51] in concentrations of 50,
100, 200 and 400 μg/cm. Amphotericine B was used as
positive control for growth inhibition.
Cytotoxicity assay
The cytotoxicity was determined by XTT method, using
the Cell Proliferation Kit II (Roche). The human prostate
cancer cell line PC-3 was maintained in RPMI 1640
medium supplemented with 10 % fetal bovine serum,
1 % L-alanyl-L-glutamin (200 mM), 1 % penicillin/strepto-
mycin and 1,6 % hepes (1 M). For the measurement of
cytotoxicity the same medium was used without antibiotics.
For PC-3 500 cells/well were seeded overnight into 96-well
plates and exposed to serial dilution of each compound for
three days.
Molecular modeling
All molecular modelling was carried out on a Linux work-
station running on a 3.5 GHz Intel Core2 Duo processor
(Santa Clara, USA). Low energy 3D structures of the thir-
teen isolated compounds were generated using the MOE
software package [52] and the Merck molecular forecefiled
[53] and saved in mol2 format. These were initially treatedwith LigPrep [54], distributed by Schrodinger, Inc (Cam-
berley, UK). This implementation was carried out with
the graphical user interface (GUI) of the Maestro soft-
ware package (New York, USA) [55], using the OPLS
force field [56–58]. Protonation states at biologically
relevant pH were correctly assigned (group I metals in
simple salts were disconnected, strong acids were
deprotonated and strong bases protonated, while topo-
logical duplicates and explicit hydrogens were added).
A set of the ADMET-related properties (a total of 46
molecular descriptors) were calculated using the Qik-
Prop program (New York, USA) [46] running in
normal mode. QikProp generates physically relevant
descriptors and uses them to perform ADMET predic-
tions. An overall ADME-compliance score, drug-
likeness parameter (indicated by #stars), was used to
assess the pharmacokinetic profiles of the compounds.
The #stars parameter indicates the number of property
descriptors computed by QikProp, which fall outside the
optimum range of values for 95 % of known drugs. The
methods implemented were developed by Jorgensen et al.
[47–49].
Conclusion
Eight known compounds have been identified from the
extracts of two species from the genus Helichrysum
(Compositae) harvested from the South West of
Cameroon (Central Africa). The results showed that the
flavonoid glycosides (3, 5) from H. foetidum exhibited
protease inhibition, while the compound (13) from H.
mechowianum contribute to the stomach protecting ef-
fects. In addition, the antibacterial and antifungal activ-
ities of compound (6) was demonstrated by the fact that
it was found to possess a potent inhibitor effect against
the tested microorganisms. The differential bioactivities
and determined constituents support the traditional use
of the species. Molecular modelling studies showed that
five of the isolated compounds showed physicochemical
properties that completely within the recommended
range for more that 95 % of known drugs, while two
compounds have only one violation.
Additional file
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